Km Biologics Co., Ltd.

Akihiro Koube

Hiroyuki Shimizu

Hiroaki Mori

Tomohiro Nishimura

Masaharu Torikai

Miyuki Matsumoto

Takahiro Katayama

Naoki Inoue

Takamasa Nagatomo

The present invention is directed to provide a modified CMV gB protein that can induce a group of antibodies including a high ratio of neutralizing antibodies that exhibit a high neutralizing activity against a CMV gB protein, in comparison with a wild type CMV gB, upon induction of immunity and that can be used in the prevention and/or treatment of CMV infection and a CMV vaccine comprising the modified CMV gB protein. The modified CMV gB protein according to the present invention is a modified CMV gB protein having an improved ability to induce body region-recognizing antibodies and comprising modification in a head region.

Modified CMV gB protein and CMV vaccine including same

An anti-HSV monoclonal antibody or an antigen-binding fragment thereof is an anti-HSV gB monoclonal antibody or an antigen-binding fragment thereof that specifically binds to herpes simplex virus (HSV) envelope glycoprotein B (gB), comprising: a heavy chain variable region comprising a heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 3, a heavy chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 4, and a heavy chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 5; and a light chain variable region comprising a light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 6, a light chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 7, and a light chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 8.

Anti-HSV GB monoclonal antibody or antigen-binding fragment thereof

The modified HSV gD protein of the present invention is a modified protein of a herpes simplex virus (HSV) envelope glycoprotein D (gD), wherein the modified HSV gD protein is derived from a wild-type HSV gD by modification of at least one of B cell epitopes having low or no neutralizing antibody-inducing activity compared to a B cell epitope present in a receptor-binding domain (RBD) (decotopes) in the ectodomain of the wild-type HSV gD, so that the modified epitope does not function as an epitope.

Modified HSV gD protein and vaccine containing same

Growing community of inventors

Kikuyo-Machi, Japan

Akihiro Koube